Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.

Also called NCT02827500

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 104 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as a collaborator
  • Duke University Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02827500
Other papers using this trial's data
  • PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial American heart journal, 2020-05 DOI, PubMed 32217365

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02827500. Randomized; no masking; primary purpose treatment. Start 2016-07 (registry gives no type); primary completion 2018-10-15 (actual). Results posted on 2019-10-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Acronym
PRIME-HF
Condition
Heart Failure
Intervention (Drug)
ivabradine
Intervention (Other)
Usual Care
Lead sponsor
Duke University (class: other)
Collaborator
Amgen (class: industry)

Record details

Record id
cardio:ct-nct02827500
Content hash
e76c42ffb6f484326bb6daecd1440ce7a948dbeed31a49e1edadb8b052f27032